These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15453119)

  • 41. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
    Dailey GE; Gao L; Aurand L; Garg SK
    Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Insulin detemir compared with NPH insulin. No significant differences identified in the studies].
    Liedholm H; Linné AB
    Lakartidningen; 2006 May 3-9; 103(18):1417, 1419-22, 1424-6. PubMed ID: 16729454
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
    Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
    Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of exercise-induced hypoglycaemia in patients with type 2 diabetes on intensive insulin therapy: comparison of insulin glargine with NPH insulin as basal insulin supplement.
    Plöckinger U; Topuz M; Riese B; Reuter T
    Diabetes Res Clin Pract; 2008 Sep; 81(3):290-5. PubMed ID: 18692269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K
    Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
    Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
    Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes.
    Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K;
    Diabetes Care; 2001 Nov; 24(11):2005-6. PubMed ID: 11679478
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes.
    Pickup JC; Renard E
    Diabetes Care; 2008 Feb; 31 Suppl 2():S140-5. PubMed ID: 18227475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
    Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
    Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
    Fujii H; Watanabe Y; Ueki A; Ohno A; Kato M; Kondo K; Takamura H; Takesue M; Nishimura H; Matsuda D; Miyakawa T
    Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Long acting insulin analogues: results of clinical studies with insulin glargine].
    Fritsche A
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S101-5; discussion S124-6. PubMed ID: 18686217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
    Rosenstock J; Dailey G; Massi-Benedetti M; Fritsche A; Lin Z; Salzman A
    Diabetes Care; 2005 Apr; 28(4):950-5. PubMed ID: 15793205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT; Thompson MF; Sauriol L
    Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
    Smeeton F; Shojaee Moradie F; Jones RH; Westergaard L; Haahr H; Umpleby AM; Russell-Jones DL
    Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
    Yki-Järvinen H; Kauppinen-Mäkelin R; Tiikkainen M; Vähätalo M; Virtamo H; Nikkilä K; Tulokas T; Hulme S; Hardy K; McNulty S; Hänninen J; Levänen H; Lahdenperä S; Lehtonen R; Ryysy L
    Diabetologia; 2006 Mar; 49(3):442-51. PubMed ID: 16456680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.